- Home
- KULR vs TIL Comparison
KULR vs TIL Comparison
Compare KULR & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KULR
- TIL
- Stock Information
- Founded
- KULR 2013
- TIL 2018
- Country
- KULR United States
- TIL United States
- Employees
- KULR N/A
- TIL N/A
- Industry
- KULR Electrical Products
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- KULR Technology
- TIL Health Care
- Exchange
- KULR Nasdaq
- TIL Nasdaq
- Market Cap
- KULR 163.0M
- TIL 177.1M
- IPO Year
- KULR N/A
- TIL 2021
- Fundamental
- Price
- KULR $3.12
- TIL $15.09
- Analyst Decision
- KULR Strong Buy
- TIL Strong Buy
- Analyst Count
- KULR 2
- TIL 5
- Target Price
- KULR $40.00
- TIL $100.67
- AVG Volume (30 Days)
- KULR 2.2M
- TIL 63.3K
- Earning Date
- KULR 11-13-2025
- TIL 11-13-2025
- Dividend Yield
- KULR N/A
- TIL N/A
- EPS Growth
- KULR N/A
- TIL N/A
- EPS
- KULR N/A
- TIL N/A
- Revenue
- KULR $12,977,975.00
- TIL N/A
- Revenue This Year
- KULR $27.50
- TIL N/A
- Revenue Next Year
- KULR $164.50
- TIL N/A
- P/E Ratio
- KULR N/A
- TIL N/A
- Revenue Growth
- KULR 35.81
- TIL N/A
- 52 Week Low
- KULR $2.44
- TIL $10.80
- 52 Week High
- KULR $43.92
- TIL $42.79
- Technical
- Relative Strength Index (RSI)
- KULR 30.70
- TIL 33.85
- Support Level
- KULR $3.88
- TIL $18.10
- Resistance Level
- KULR $4.35
- TIL $20.11
- Average True Range (ATR)
- KULR 0.23
- TIL 1.13
- MACD
- KULR -0.10
- TIL -0.31
- Stochastic Oscillator
- KULR 17.48
- TIL 15.71
About KULR KULR Technology Group Inc.
KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems, artificial intelligence and Cloud computing, energy storage, 5G communication technologies, and other consumer and industrial devices.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.